Filtered By:
Specialty: Drugs & Pharmacology
Drug: Clopidogrel

This page shows you your search results in order of relevance. This is page number 2.

Order by Relevance | Date

Total 241 results found since Jan 2013.

CYP2C19 Loss-of-Function Variants Associated with Long-term Ischemic Stroke Events During Clopidogrel Treatment in the Chinese Population
This study aims to determine whether CYP2C19 loss-of-function (LoF) variants were associated with long-term ischemic stroke risk in Chinese primary care patients treated with clopidogrel. Patients treated with clopidogrel were ascertained from a Chinese Electronic Medical Record linked with biobank for a retrospective cohort study. Their medical information was examined for the period from January 2018 to December 2021. Two CYP2C19 major loss of function variants (*2:rs4244285, *3: rs4986893) were genotyped. The clinical outcome was ischemic stroke event. Cox regression analysis was used to evaluate the association between...
Source: Clinical Pharmacology and Therapeutics - August 22, 2023 Category: Drugs & Pharmacology Authors: Peng Wu Ziqing Liu Zijian Tian Benrui Wu Jian Shao Qian Li Zhaoxu Geng Ying Pan Ke Lu Qiang Wang Tao Xu Kaixin Zhou Source Type: research

Antiplatelet Use in Ischemic Stroke
CONCLUSIONS: Although good evidence exists for the use of certain antiplatelet agents postischemic stroke, there are considerable opportunities for future research to investigate personalized therapies. These include screening patients for platelet polymorphisms that confer antiplatelet resistance and for randomized trials including more racially diverse populations.PMID:35094598 | DOI:10.1177/10600280211073009
Source: The Annals of Pharmacotherapy - January 31, 2022 Category: Drugs & Pharmacology Authors: Marharyta Kamarova Sheharyar Baig Hamish Patel Kimberley Monks Mohammed Wasay Ali Ali Jessica Redgrave Arshad Majid Simon M Bell Source Type: research

The Efficacy and Safety of 3 Types of Interventions for Stroke Prevention in Patients With Cardiovascular and Cerebrovascular Diseases: A Network Meta-analysis.
Abstract PURPOSE: The goal of this study was to compare the relative efficacy and safety of different types of interventions for stroke prevention in patients with cardiovascular and cerebrovascular diseases. METHODS: This network meta-analysis (NMA) was conducted with a random effects model of Bayesian framework using Stata version 12.0. Odds ratios (ORs) and their credible intervals (CrIs) were applied for the efficacy and safety evaluation of various medical interventions, including aspirin, dipyridamole, ticlopidine, warfarin, and apixaban. In addition, the ranking of probability of every clinical outcome...
Source: Clinical Therapeutics - June 10, 2017 Category: Drugs & Pharmacology Authors: Sun Q, Chang S, Lu S, Zhang Y, Chang Y Tags: Clin Ther Source Type: research

Investigating Real-World Clopidogrel Pharmacogenetics in Stroke Using a Bioresource Linked to Electronic Medical Records.
In conclusion, we have demonstrated the clinical impact of CYP2C19*2 on clopidogrel efficacy using a purely EMR approach. This suggests that the risk in the ischemic stroke population may be particularly high. This article is protected by copyright. All rights reserved. PMID: 28653333 [PubMed - as supplied by publisher]
Source: Clinical Pharmacology and Therapeutics - June 27, 2017 Category: Drugs & Pharmacology Authors: Tornio A, Flynn R, Morant S, Velten E, Palmer CNA, MacDonald TM, Doney ASF Tags: Clin Pharmacol Ther Source Type: research

A noninferiority confirmatory trial of prasugrel versus clopidogrel in Japanese patients with non-cardioembolic stroke: rationale and study design for a randomized controlled trial - PRASTRO-I trial.
CONCLUSIONS: This article presents the study design and rationale for a trial investigating the noninferiority of prasugrel to clopidogrel sulfate with regards to the inhibitory effect on primary events in patients with non-cardioembolic stroke. PMID: 29463150 [PubMed - as supplied by publisher]
Source: Expert Opinion on Pharmacotherapy - February 25, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Age-dependent association of CYP2C19 polymorphisms with clinical outcome of clopidogrel therapy in minor stroke patients with large-artery atherosclerosis
ConclusionsCarriage of the CYP2C19 LOF allele may prevent expected clinical outcome during clopidogrel therapy in young LAA-associated minor stroke patients, whereas not in older patients.
Source: European Journal of Clinical Pharmacology - June 4, 2020 Category: Drugs & Pharmacology Source Type: research

Influence of CYP2C19 polymorphisms on platelet reactivity and clinical outcomes in ischemic stroke patients treated with clopidogrel.
In conclusion, carriage of the CYP2C19 LOF allele has significant influence on clopidogrel response and prognosis in patients with ischemic stroke. PMID: 25489921 [PubMed - as supplied by publisher]
Source: European Journal of Pharmacology - December 6, 2014 Category: Drugs & Pharmacology Authors: Qiu LN, Sun Y, Wang L, Han RF, Xia XS, Liu J, Li X Tags: Eur J Pharmacol Source Type: research

Associations of CYP3A4, NR1I2, CYP2C19 and P2RY12 polymorphisms with clopidogrel resistance in Chinese patients with ischemic stroke.
CONCLUSION: The individuals with both the CYP2C19(*)2 allele and hypertension are at high risk of CR during anti-thrombosis therapy. The CYP3A4(*)1G allele, P2RY12 (rs2046934) C allele and NR1I2 (rs13059232) CC genotype may be protective factors for CR. The associated SNPs studied may be useful to predict clopidogrel resistance in Chinese patients with ischemic stroke. PMID: 27133299 [PubMed - as supplied by publisher]
Source: Acta Pharmacologica Sinica - May 1, 2016 Category: Drugs & Pharmacology Authors: Liu R, Zhou ZY, Chen YB, Li JL, Yu WB, Chen XM, Zhao M, Zhao YQ, Cai YF, Jin J, Huang M Tags: Acta Pharmacol Sin Source Type: research

Therapeutic Challenges in Patients With Noncardioembolic Acute Ischemic Stroke in Need of Double Antiplatelet Therapy for Coronary Artery Disease
Conclusions: In the acute phase of an IS, maintenance or initiation of DAPT therapy imposed by CHD relies, on one hand, on the risk of hemorrhagic transformation of the brain injury and, on the other hand, on the risk of stent thrombosis in the coronary arteries. The management of these patients must be carried on by a vascular team, on an individualized basis.
Source: American Journal of Therapeutics - March 1, 2019 Category: Drugs & Pharmacology Tags: Systematic Reviews Source Type: research

Risk factors of recurrent ischemic events after acute noncardiogenic ischemic stroke.
CONCLUSION: MPV, ADP% and MA were risk factors of recurrent ischemic events after acute noncardiogenic ischemic stroke. Urgent assessment and individual drug therapy should be offered to these patients as soon as possible. PMID: 31663472 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - October 27, 2019 Category: Drugs & Pharmacology Authors: Zhang L, Li X, Wang D, Lv H, Si X, Li X, Sun Y, Wang D, Chen K, Kang X, Lou X, Zhang G, Ma N Tags: Curr Pharm Des Source Type: research

A study of microRNA-223 in evaluating platelet reactivity in patients with acute ischemic stroke
J Physiol Pharmacol. 2022 Feb;73(1). doi: 10.26402/jpp.2022.1.11. Epub 2022 Jul 4.ABSTRACTTo investigate the relationship between plasma microRNA-223 expression and platelet reactivity in patients with acute ischemic stroke (AIS) and to evaluate its predictive value in clopidogrel resistance or high on-treatment platelet reactivity (HTPR). A total of 120 patients with acute ischemic stroke were screened in this study, and 60 patients were included in the acute ischemic stroke group according to the inclusion criteria and platelet reactivity after clopidogrel treatment. control group was 60 non-ischemic stroke patients hosp...
Source: Journal of Physiology and Pharmacology - July 6, 2022 Category: Drugs & Pharmacology Authors: D-L Wang X Li R-N Wang Y Sun X-S Xia W-J Tian L Wang Source Type: research